Effects of verapamil combinations with enalapril or indapamide on plasma, vascular and platelet hemostasis and biochemical markers of endothelial dysfunction in patients with arterial hypertension and metabolic syndrome

The combination of verapamil retard and enalapril, or verapamil retard and indapamide SR similarly and significantly increased high-density lipoprotein cholesterol and stable NO2 metabolite levels, reducing platelet aggregation in patients with metabolic syndrome (MS). Compared to the combination of...

全面介紹

書目詳細資料

發表在:	Российский кардиологический журнал
Main Authors:	N. M. Krasnova, T. P. Kalashnikova, A. I. Vengerovsky, E. M. Idrisova, I. V. Kulagina, T. E. Suslova, O. V. Gruzdeva, S. V. Kremeno, N. M. Zheltonogova, A. A. Shishkina, R. S. Karpov
格式:	Article
語言:	俄语
出版:	«FIRMA «SILICEA» LLC 2008-06-01
主題:	metabolic syndrome arterial hypertension platelet aggregation willebrand factor no2 verapamil enalapril indapamide
在線閱讀:	https://russjcardiol.elpub.ru/jour/article/view/1572